BiotechTube
Home/Pipeline/NRP2945

NRP2945

Lennox‑Gastaut Syndrome

Phase 2Active

Key Facts

Indication
Lennox‑Gastaut Syndrome
Phase
Phase 2
Status
Active
Company
CuroNZ, CuroNZ, CuroNZ

About CuroNZ

Curonz develops CXCR4‑agonist peptide therapeutics to treat ultra‑orphan epileptic encephalopathies.

View full company profile

About CuroNZ

Curonz develops CXCR4‑agonist peptide therapeutics to treat ultra‑orphan epileptic encephalopathies.

View full company profile

About CuroNZ

Curonz develops CXCR4‑agonist peptide therapeutics to treat ultra‑orphan epileptic encephalopathies.

View full company profile

Therapeutic Areas

NeurologyEpilepsy